Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Finished Goods: 2015-2024

Historic Finished Goods for Amphastar Pharmaceuticals (AMPH) over the last 10 years, with Dec 2024 value amounting to $39.4 million.

  • Amphastar Pharmaceuticals' Finished Goods rose 11.70% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.7 million, marking a year-over-year increase of 11.70%. This contributed to the annual value of $39.4 million for FY2024, which is 58.14% up from last year.
  • Amphastar Pharmaceuticals' Finished Goods amounted to $39.4 million in FY2024, which was up 58.14% from $24.9 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Finished Goods high stood at $39.4 million for FY2024, and its period low was $12.5 million during FY2020.
  • Moreover, its 3-year median value for Finished Goods was $24.9 million (2023), whereas its average is $27.7 million.
  • Its Finished Goods has fluctuated over the past 5 years, first dropped by 20.34% in 2020, then surged by 58.14% in 2024.
  • MRY analysis of 5 years shows Amphastar Pharmaceuticals' Finished Goods stood at $12.5 million in 2020, then skyrocketed by 40.99% to $17.7 million in 2021, then rose by 6.97% to $18.9 million in 2022, then skyrocketed by 31.99% to $24.9 million in 2023, then surged by 58.14% to $39.4 million in 2024.
  • Its Finished Goods was $39.4 million in FY2024, compared to $24.9 million in FY2023 and $18.9 million in FY2022.